Sucralphate-technetium scintigraphy in inflammatory bowel disease: experience in 23 patients.
Serial abdominal scanning after the oral administration of sucralphate-99mTc was performed in order to determine the extent of active inflammatory bowel disease in 15 patients with Crohn's disease and in 8 patients with ulcerative colitis. Scintigraphic data were compared with those obtained by endoscopy and radiology in all patients. True positive scans were obtained in 6 (40%) patients with Crohn's disease and in 3 (38%) patients with ulcerative colitis. Overall, sensitivity was higher in colonic disease than that in ileal disease. In 4 (17%) patients, false negative scans were obtained and in the remaining 10 (44%) patients, localisation of the inflammatory bowel disease by the isotope was completely inaccurate. Since sensitivity of the sucralphate-99mTc scintigraphy appears to be low, its widespread use in the screening for inflammatory bowel disease or in assessing the extent of disease involvement cannot be advocated at this moment.
R N
RN
Zeijen
H A
HA
van der Pol
G J
GJ
Teule
L P
LP
Bos
J A
JA
Flendrig
L G
LG
Engels
D000328:Adult; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000000981:diagnostic imaging*; D009942:Organometallic Compounds; D015609:Organotechnetium Compounds; D011237:Predictive Value of Tests; D011877:Radionuclide Imaging; D013392:Sucralfate; D013667:Technetium
D009942:Organometallic Compounds; D015609:Organotechnetium Compounds; C038248:technetium Tc 99m sucralfate; D013392:Sucralfate; D013667:Technetium